JiangXi Tianxin Pharm Co Ltd
JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as i… Read more
JiangXi Tianxin Pharm Co Ltd (603235) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.07 Billion CNY
Based on the latest financial reports, JiangXi Tianxin Pharm Co Ltd (603235) has total liabilities worth CN¥1.07 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JiangXi Tianxin Pharm Co Ltd - Total Liabilities Trend (2020–2024)
This chart illustrates how JiangXi Tianxin Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
JiangXi Tianxin Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of JiangXi Tianxin Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing TDH Technology Co. Ltd. A
SHE:301378
|
China | CN¥264.18 Million |
|
Verano Holdings Corp
OTCQX:VRNOF
|
USA | $1.02 Billion |
|
Anji Foodstuff Co Ltd
SHG:603696
|
China | CN¥30.40 Million |
|
GeoPark Limited
SA:GPRK34
|
Brazil | R$987.26 Million |
|
Paisalo Digital Limited
NSE:PAISALO
|
India | ₹39.04 Billion |
|
OK Science & Technology Co. Ltd. A
SHE:001223
|
China | CN¥576.76 Million |
|
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
|
USA | $10.31 Million |
|
IDI S.C.A.
PA:IDIP
|
France | €79.35 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down JiangXi Tianxin Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JiangXi Tianxin Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JiangXi Tianxin Pharm Co Ltd (2020–2024)
The table below shows the annual total liabilities of JiangXi Tianxin Pharm Co Ltd from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥987.41 Million | +15.19% |
| 2023-12-31 | CN¥857.21 Million | +37.82% |
| 2022-12-31 | CN¥621.98 Million | -40.40% |
| 2021-12-31 | CN¥1.04 Billion | -40.72% |
| 2020-12-31 | CN¥1.76 Billion | -- |